The Public Stake in Medical Research I have been asked to speak about responsibility for medical research. True to the purpose of this forum, I shall concentrate on the future. My thesis is that a new force is entering the field of science which will certainly alter this responsibility. This new force is the public, operating through government. The genesis of this force is success. Scientific research has become so successful and popular that it has outgrown the resources of its private sponsors and has become dependent on the taxpayer for most of its support. In my country, where this trend has been most noticeable, the taxpayer, who started out with an overabundance of enthusiasm and hope, is now beginning to ask embarrassing questions. He has not yet reached the point of paraphrasing Clemenceau and saying that science is too important to be run by the scientists, but he wants a place above the salt at the conference table where he can ask some blunt questions about where his money is being spent, for what purpose and with what results.
This has created a certain amount of uncertainty about the future course of medical research. Because this development may have some relevance to trends in the United Kingdom, present or future, I have thought it might be useful to discuss it with you. But before we get into the present and into speculations about the future, I think it would be helpful to indulge in a little prologue. I shall understandably focus my comments on pharmaceutical research.
Except for a few remarkably happy chance observations, experimental research in medicine is hardly a century old. The organized search for new knowledge across the broad spectrum of the biomedical sciences by tens of thousands of trained men and women is a post World War II phenomenon. The transition from the early experimentalists to the modern bureaucracies of research, such as the one over which I preside, has been a series of major steps, each built on the success of its predecessor. Let us examine two of these steps.
The first major step was that of industry to organize its own pharmaceutical research. The pioneers were European companies, including several in your own country. We Americans were quite tardy. How tardy, can be understood when I tell you that the main speaker at the dedication of Merck's first laboratory in 1933 -and we were among the pathfinderswas the beloved Nobel laureate, Sir Henry Dale, who had moved his research three decades before from University College to the Wellcome Physiological Research Laboratories, the research arm of Burroughs Wellcome & Co. It is of more than academic interest that Mr Wellcome was an American; that he founded this laboratory back in 1894; that nothing of importance came out of it until a decade later when the young Henry Dale joined themagainst the advice of his friends but on the always respected premise that he would have freedom to pursue his own line of research.
Though we Americans were encouraged by what we saw across the Atlantic, we still had to face the decision de novo in our own environment. The success of the venture, of course, would depend on the quality of scientist we could attract. Here we ran into some pretty high fences. I shall describe these fences because I understand that you in this country find them occasionally still standing in place. These were the obstacles erected by both industry and science to keep each other out.
One fence protected academic science from exploitation by institutions that needed to show a tangible and short-term return on investment and that might therefore lure science away from its historic mission of accumulating new knowledge. On its side, industry, concentrating on the day-today problems of raw materials, production, sales and competition, could see no earthly need to welcome into its midst a band of theorists, scientific or otherwise, who would surely try to use new knowledge as a lever to pry apart the status quo. All this was immensely bolstered by strong cultural, almost tribal, beliefs. University professors derided the value systems of the market and looked upon potential contamination with Calvinistic misgivings and social scorn. The industrialists, in return, had their own ways of feeling superior.
When George Merck in the early 1930s decided to break through this barrier and test the hypothesis that the state of knowledge in the biomedical sciences had reached the point where first-rate scientists could be as productively creative for and within a pharmaceutical company as behind the wall of a university campus, he set out to find and attract a top-notch pharmacologist. He turned for help to the distinguished pharmacologist, Alfred Newton Richards, who worked for a period during World War I with Henry Dale, then a department director at the National Institute for Medical Research. But the key professional society, the American Society for Pharmacology and Experimental Therapeutics, flatly prohibited any of its members from joining industry. In an attempt to break this tribal rigidity, Dr Richards, on becoming an advisor to Merck, offered his resignation from the Society. The Society rejected his resignation but refused to change its rule. Richards, unable to persuade any member in good academic standing to defy his peers, was forced to turn to Europe. The eminent teacher and investigator, Hans Horst Mayer of Vienna, came up with a young Austrian pharmacologist, Hans Molitor, who in 1932 agreed to try Merck for one year. He stayed for more than a quarter of a century.
It had required more than personal persuasiveness to get Molitor and others who followed him to risk their careers on Merck's experiment in research. It had required a careful plan of how to set up a research laboratory in a pharmaceutical company in such a way that some of the best rewards of a university environment could be added to those of a corporation in a harmonious blend. As these policies were evolved they included the following five major incentives for members of the laboratory:
(1) Freedom, within reasonable limitations, to work on problems of their own choosing, including the opportunity to do basic research.
(2) Freedom to publish and present papers at professional meetings, thus offering an opportunity for scientists to add to the general store of knowledge and to get recognition from their peers for their achievements. This was a sharp departure from the traditional secrecy that had always surrounded industrial research.
(3) The opportunity to discover and develop actual therapeutic agents that would control disease and alleviate human suffering.
(4) Close collaboration with leading scientists in related fields in universities, medical schools and hospitals.
(5) An interdisciplinary approach to the solution of medical problems, unavailable in the academic environment.
When we decided to bring scientists into industry, we went all the way. This has happened in industry after industry in the United States. By respecting the integrity, value systems, and contributions of scientists, we have been able to put them on an equal footing with their colleagues in the universities, both professionally and socially. By making them equal partners with other members of management, they have been able to play a creative and successful role in the growth of individual companies. These factors, in my opinion, have had as much to do with the socalled brain drain and the technological gap as the actual dollars we have poured into research and development.
This point was underlined in your country last year by the so-called Jones Report entitled 'The Brain Drain'. In commenting on this report, the journal Chemistry in Britain said: 'Industry, with honourable exceptions, still regards scientists as an unavoidable nuisance . . . and many universities still enjoy basking in the warmth of a tradition that exists only in the imagination. . . An even stronger magnet [than money] is the desire to be treated as socially equal, responsible and useful individuals who have, and are seen to have, a future in their chosen vocation.'
On our side of the Atlantic there are two strong social forces that have been working in our behalf. We have inherited a very practical streak from our pioneer days. We applaud anyone who can do something better.
The other helpful force also grows out of our history. We have always tended to be a merit-ocracy. There was so much work to be donemuch of it new -in building a nation that we early devised a rather mobile and opportunistic social hierarchy. If we had to give social rewards to an occupation in order to get a new and needed job done, we have not hesitated to do so.
Thus, when medical progress needed scientists in the pharmaceutical industry, the social barriers that were preventing them from moving from a university to a company laboratory came tumbling down. Dramatic proof of this came in 1952 when the very organization that had refused to allow any of its members to transfer to industry, the American Society for Pharmacology and Experimental Therapeutics, elected Dr K K Chen, then director of pharmacological research for Eli Lilly and Company, to its presidency and eleven years later elected to this same high office another pharmacologist from the pharmaceutical industry, Dr Karl Beyer, the senior vice-president of the Merck Sharp & Dohme Research Laboratories.
Another kind of proof is the way scientists have moved up into the top ranks of American management. Scores of corporations, including my own, have elevated their research heads to membership on their Boards of Directors, where the highest policy questions are decided. Dr Vannevar Bush, the leader of America's scientific effort during World War II, was chairman of the Merck Board of Directors from 1957 to 1962, and Dr A N Richards served as a member of that board for eleven years.
All these factors were reinforced by one moreluckwhen Merck ventured into research in 1933. Our timing turned out to be perfect. Two years after Sir Henry Dale dedicated our first laboratory, Domagk discovered the antibacterial effectiveness of Prontosil, the French improved it with sulphanilamide and your own May & Baker added its significant contributions. This was coincidental with several major developments in the vitamin field such as ascorbic acid, thiamine, pyridoxine and riboflavine. The age of chemical medicine opened, and the new Merck laboratories were able to make major contributions from the very beginning. Pharmaceutical research not only was successful but it became the most dynamic factor in the growth of the industry.
I trust you will forgive me if at this point I indulge myself with one digression. It is the first time since I was involved in the early work on penicillin that I have had a public opportunity in your country to pay tribute to the important role that Britain's pioneer work with penicillin played not only in the development of our industry but also in the great flowering of medical research that followed the war. Since you are all familiar with the penicillin story, I shall confine myself to one sidelightwhat happened when Florey, Chain and Heatley brought samples of their mould to the United States. It was touch and go as to whether anything would happen. There was great scepticism about the real significance of their experiments. We have a memorandum in our company research files from an eminent outside scientific consultant who urged us quite fervently not to waste our time on penicillin; it was far too unstable and unpromising; besides, we had the sulpha drugs and what could penicillin do that the sulpha drugs could not? Fortunately, the American companies paid no attention to the sceptics. Norman Heatley of Oxford came to work with me personally in our laboratories for several months to show us how he isolated useful penicillin concentrates from fermentation broths.
But, more important for the scale of the American effort, Florey went down to Philadelphia to see his old friend, A N Richards, who had just been appointed to head medical research under Vannevar Bush, President Roosevelt's science advisor. Over a luncheon table Florey told Richards the story of the Oxford team's work with penicillin. On the spot Richards decided to back penicillin with all the power the country could put behind it. Asked later why he took this risk, and so quickly, Richards replied: 'Florey had worked in my laboratory. I knew he was a fine scientist. As such, he was incapable of telling an untruth.' Thus, on the basis of one man's judgment of another man's character, medicine's first antibiotic started down the development road toward its historic achievements with all the effective scientific support our two countries could give it.
As I said earlier, penicillin's success played a significant role in the flowering of medical research in our country since the war, as did atomic fission in the great upsurge of the physical sciences. These two wartime activities dramatized the enormous potential of organized scientific research and development on a large scale. As a result, science, which only recently had expanded from its ancient home in the university into a new home, industry, took the second major stepthis time into the public arena.
The most important result in my country of this second step has been the enormous infusion of tax money into research. This year it is expected that the United States will spend 25 thousand million dollarsor better than 10 thousand million poundson research and development, of which the federal government will contribute 16-5 thousand million dollars, or almost 7 thousand million pounds. This has created great opportunities for progress undreamed of a few short years ago. But it has also immensely complicated the decisionmaking process in research. For the first time in history the public has a voice in the direction of science. Because the public is footing most of the bill, it now has the dominant voice. This is a radical, perhaps inevitable, extension of the democratic experiment. We do not yet know whether it will work out well.
Some of the most spectacular developments in our science in the United States have been in the bio-sciences. Public hopes were raised, not only by your penicillin, but by a series of breakthroughs that followed swiftly: streptomycin, cortisone, vitamin B12, broad-spectrum antibiotics and the early tranquillizers. Then, in 1955, came the most highly publicized of all -Salk vaccine. Whereas the earlier advances were primarily the result of privately sponsored research, the Salk vaccine was made possible by research supported by small contributions from millions of Americans. The message reached the public and its elected representatives. The next year Congress doubled the appropriations for the National Institutes of Health and declared in effect that it would henceforth be national policy to conquer disease through research, no matter how long, costly or difficult the task.
Thus, the new era in medical research-basic and appliedwas launched. Government support has multiplied until during the last fiscal year it amounted to about 1-4 thousand million dollars or about 500 million pounds. This support has been based on faith that as science unravelled some of the mysteries of life, bit by tiny bit, it would be able eventually to return priceless dividends to our people and to others around the world in the form of healthier, happier and longer lives.
To sum up our experience in the United States with public participation in the decision-making process in that medical research which it supports through its government, I would say that to date it has been extraordinarily satisfactory. The public has been generous to a fault. Through our Congress, it delegated to members of the scientific community, in and out of government, almost the entire responsibility for deciding where the money was to be spent. They have shown remarkable wisdom and foresight; they have devoted the bulk of the public funds to medical science's longrange needs for both basic research and for trained manpower.
Although the public has been unexpectedly patient with the results of its support of basic research (and remember there are few results that the average citizen can graspeven after they have been explained), there are signs that this patience is beginning to wear a little thin. After all, the public thought it was toldbecause this is what it hoped and was able to understandthat tax money would be used to control, prevent or cure disease. As one Senator once put it, 'Who is going to vote in Congress against a cure for cancer?' It has been well over a decade since our Congress embarked on this course and so far no major new disease has been cured by the government-supported efforts or indeed by our total national effort though an enormous amount of new knowledge has been acquired and new horizons have been opened up for medicine. With the combination of these massive public and private efforts, there has been highly significant progress in every branch of therapeutics, including cancer, but even the medical profession is more aware of what has not rather than what has been accomplished. We could hardly expect the. public to be less impatient. Leaving aside its expectations -which unfortunately were somewhat unrealisticits own money has gone into this effort to the tune of about 3 thousand million pounds.
The impatience that has sprung from this combination of factors has begun to be translated into political language. All sorts of efforts are now being made in the United Statessome of them wise, some of them notto put pressure on knowledge to produce practical results. Some politicians are asking that much of the government funds should be diverted from basic research into development of therapeutic agents.
This demand is founded on a misconception that basic knowledge in the life sciences is now so vast that it is more than ready for major breakthroughs in medicine. Indeed, biomedical research has come a long way. But how far is it from its practical goal? Unfortunately, there are many miles to go. When the new era of substantial government support of medical research began in 1956, the life sciences were probably half a century behind the physical sciences in the accumulation of knowledge of the kind and depth that leads to major discoveries. Though biomedical knowledge is catching up fast, there is still no escaping its primitive state today or the size of the task ahead. The situation stems from the complexity of life processes themselves. In the human body, research is dealing with something like 100,000 or more biochemical processes. The number of unknown variables with which it has to cope is well beyond its present comprehension. So there is no choice; if research is to conquer disease, a vast proportion of it must stick to the central task of acquiring basic knowledge. This leads to the thought that we need to plan with greater vision for an effective division of effort among the various public and private resources if our total investment in health is to yield beneficial returns to society.
Let me give you an example of how these roles can blend. Over the past thirty years, Merck has devoted some of its best scientific efforts to research on arthritis, research that is both basic and developmental. It was a young Merck chemist, Dr Lewis H Sarett, who, at the age of 26, first synthesized cortisone after some of the best steroid chemists in the world had tried and failed. This was in 1944, and it was the first major breakthrough for arthritis patients.
Cortisone was followed by improvements made by scientists in several companies in the industry, including ours. After a ten-year effort, we made another stride in our laboratories when we introduced the nonsteroid indomethacin which has been a boon to several million patients throughout the world.
But there is still a deep dissatisfaction connected with this story. It is a dissatisfaction for us, and other scientists in the pharmaceutical industry, and, most important, for the medical profession and for the millions of victims of rheumatoid arthritis and related diseases. Neither we nor anybody else has found either the cure for or, for that matter, the cause or causes of these diseases. All we have discovered are better methods to relieve suffering and to return invalids to productive lives. This is important; but we still have before us the challenge to finish the job. What deters us from success is the lack of knowledge and basic understanding of these disease3. To acquire them takes time, money, resources and people of many disciplines and probably with no solution to the disease problems for some years to come. No one company can do enough nor has it the required technical capacity. But a nation or a community of nations can.
What has been said about rheumatoid arthritis is equally true about most diseases, since, in the main, all we can do is to alleviate symptoms. This unfortunate situation is bound to change as we continue our present course of acquiring both knowledge and understanding all along the broad spectrum of the life sciences. Progress in our comprehension of cell biology is already creating new vistas in medicine and will change our whole approach to the cure of disease as more knowledge accumulates. Only governments have the resources to support fully such vital and hopeful quests.
But there are many competing demands for the tax dollar and the citizen begins to wonder whether funds might be better devoted to cleaning up the cities, the air and the rivers or to providing better education and housing; all these are immediate needs, progress towards the satisfaction of which he can understand and can often see with an unaided eye.
For the first time since the new era in medical research opened ten years ago, our Congress has really put the brakes on expansion. Our govern-ment's budget is getting out of hand and basic research looks like the soft underbelly, unprotected and open for attack. Though I would be quite surprised if fiscal considerations in Britain were not having the same effect, I would prefer to talk about events in my own country of which I have some knowledge and let you translate these events into the idiom of your own experience.
The reaction to this slowdown in expenditure has been as predictable as the slowdown itself. Some of my colleagues in the life sciences are working hard to build understanding and new institutions to cope with changed conditions. Others, who were quite happy when government funds for research were growing at several times the rate of the economy as a whole, are now muttering about the fickleness of the public and the obtuseness of politicians. Some prefer to light a candle, others to curse the darkness. I prefer to take the unpopular position that the slowdown is not all bad. If we face its implications realistically, we should be able to benefit in two ways. First, we all accept the obvious: medical research is only one of a vast number of desirable alternative investments from society's point of view. Tnis means that we will have to learn to live within certain financial limitations. If we want to make faster progress with a slower rate of increase in funds, we will have to plan better, train and select better and improve our leadership and efficiency.
One luxury we will not be able to afford. We will be robbing the future if in trimming the budget government plays safe and cuts off support from those who have not yet made their reputations. Under pressure any bureaucracy is likely to follow this course. Clearly, it will be the responsibility of industry, foundations and the universities to see that the young investigators with promise who would otherwise be left behind are identified, encouraged and helped. In the case of industry, this will be difficult, but we should be more willing to gamble than government.
The second benefit that will come from a slowdown in the rate of expenditures is that medical research will be forced to recognize that the public's price for partnership is a major role in decision-making. It is clear that we cannot have informed decision-making by the public in medical research until we have a scientifically informed public. The language of politics is indispensable to the creation of such an informed citizenry, because it is the professional task of politicians and government administrators to translate the goals of their constituents into specific programmes and then to persuade and explain. In my country medical research has had the great good fortune of having, as head of the National Institutes of Health, Dr James Shannon, who understands the language of politics and has been able to use it to build a programme of basic research in the life sciences that, in quality and scope, is unrivalled.
The dramatic announcement last month that a team under Arthur Kornberg at Stanford had duplicated artificially the DNA found in the Phi 174 virus was the result of one of the research efforts Dr Shannon has supported. It is notable that the President of the United States, a man quite fluent in the language of politics, participated in the announcement of Kornberg's successful experiment.
Science was originally responsible only to the few. It now has to adapt itself to its new responsibilities to the many. This means that scientists, in medicine and other fields, must get into public affairs because public affairs are getting into science. This, I feel sure, is as true for Britain as it is for my country.
As scientists venture into public affairs, it might be useful to remember the constructive role they played when, just a few decades ago, they ventured into industry. The fear at that time, as has been pointed out, was that industry would lure science away from its historic mission of accumulating knowledge. This did not happen because the scientific fraternity persuaded industry to build a co-operative partnership with the universities, each partner doing that part of the job for which it was best suited. The universities, medical schools and hospitals remained committed to basic research, mainly by individual investigators. The pharmaceutical industry took on the major assignment of turning the results of this research into new tools of therapy. In order to do this effectively, company scientists established and maintained close working relationships with their academic peers and devoted a significant part of their time and effort to basic research, mostly of an interdisciplinary character. This new relationship strengthened both partners. Now a force even more powerful than industry has entered the picturethe taxpayer. Through government, he can insist on having his way. Using the power of the purse, government can undermine the roles of academic or pharmaceutical industry research, or both. Or, alternatively, the academic, scientific and medical fraternities can enter the public arena with their skills at persuasion and their enormous influence to steer this new force into constructive channels. If government can follow the earlier path outlined above, it will lead to a smooth-working partnership in which each partner is doing what he does best. The academic world, industry and government would each be strengthened by such a new relationship, and mankind would benefit from a new rate of progress toward the common goala healthier life for everyone. The incentive to do medical research stems from many quarters which -although united in purposeare nevertheless becoming more widely separated from one another in this era of specialized disciplines and organizations.
Had the early denizen of my home town, Theophrastus Bombastus Paracelsus, been asked who was responsible for medical research, he would undoubtedly have given a simple and straightforward answer, to wit: Medical research is my responsibility and that of my peers. And the position did not basically change until perhaps a century ago, when the special medical disciplines and all the basic medical sciences, including biochemistry, came of age. Meanwhile, the catalogue has become much longer since epidemiology, public health, population control, nutrition, radiobiology, genetics, and many other disciplines including aviation and space research have been added to the areas of scientific endeavour from which medical research takes its cues.
Today, medical research is not only the preoccupation of the medical schools and science faculties of universities, it has become a noble prerogative of private and public research institutes, of defence establishments, of national governments and international organizations, of charitable institutions and foundations, and, last but not least, ofa highly developed pharmaceutical industry whose livelihood depends almost entirely on medical research.
But let me return to the question: Whose responsibility is medical research? And another question which follows logically: To whom are those engaged in medical research responsible?
The latter question is easy to answer. Since all research costs money, those who carry out research are responsible to those who finance it: the government agencies, the international organizations, the private foundations, the university administrations, the industrial managements, the stockholders and the taxpayers.
In evaluating the research for which they are paying, the donors will of course consider the degree of excellence of the work performed. But in medical research there enters a second consideration which would not apply in, say, mathematical research. It is the usefulness of the results.
By definition, medicine is an applied science or, better, is an application of science to the art of medicine. It is expected to produce results which, over and above the accumulation of knowledge,
